You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

4 Items
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
New Drug Funding Program
    Ipilimumab - Previously Untreated Advanced Unresectable Melanoma
New Drug Funding Program
    Ipilimumab - Previously Treated Advanced Unresectable Melanoma
Nov 2017
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Apr 2019
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab – Metastatic Renal Cell Carcinoma
New Drug Funding Program
    Nivolumab plus Ipilimumab – Metastatic Renal Cell Carcinoma
May 2019
Cancer Type: Gastrointestinal, Colorectal     
Intent: Palliative
Drugs Used:
nivolumab (Unfunded),
ipilimumab (Unfunded)
Mar 2019